Chronic LDH Elevation after Left Ventricular Assist Device Implantation
نویسندگان
چکیده
A 61-year-old woman who underwent HeartMate II left ventricular assist device placement for non-ischemic cardiomyopathy developed elevated lactate dehydrogenase within two weeks after implantation. After eight months of observation and several hospital admissions during which there was no evidence of pump thrombosis, she presented with clinically manifest hemolysis. During pump exchange there was notable pannus formation on the inflow cannula of the left ventricular assist device. The pannus around the inflow likely existed for several months, limiting the flow and creating a lowgrade hemolysis and this low flow state stimulated thrombus formation triggering gross hemolysis. Thoratec analysis of the pump confirmed that the clot was present for about 5 days. Lactate dehydrogenase normalized after pump exchange.
منابع مشابه
Design an Equivalent Left Ventricular Assist Device for Medical Equipment Labs
LVAD is a mechanical pump supporting a weak heart function and blood flow. Sometimes, the heart may not recover fast enough to take over the pumping action immediately after surgery, in such patients a temporary support device has been employed to maintain the pumping action until the patient’s own heart recovers. This device can be considered as a temporary alternative before the process of ar...
متن کاملUnexpected abrupt increase in left ventricular assist device thrombosis.
BACKGROUND We observed an apparent increase in the rate of device thrombosis among patients who received the HeartMate II left ventricular assist device, as compared with preapproval clinical-trial results and initial experience. We investigated the occurrence of pump thrombosis and elevated lactate dehydrogenase (LDH) levels, LDH levels presaging thrombosis (and associated hemolysis), and outc...
متن کاملOrthotopic heart transplant versus left ventricular assist device: a national comparison of cost and survival.
OBJECTIVES Orthotopic heart transplantation is the standard of care for end-stage heart disease. Left ventricular assist device implantation offers an alternative treatment approach. Left ventricular assist device practice has changed dramatically since the 2008 Food and Drug Administration approval of the HeartMate II (Thoratec, Pleasanton, Calif), but at what societal cost? The present study ...
متن کاملPimobendan in Chronic Right Heart Failure in a Left Ventricular Assist Device Patient
We report the case of a 76-year-old patient who developed chronic right heart failure 1 year after left ventricular assist device implantation due to ischemic cardiomyopathy. Initial recompensation was achieved through dobutamin, sildenafil, and levosimendan treatment. Yet, discharge was successful only after the off-label use of the oral calcium sensitizer pimobendan. Ten months after discharg...
متن کاملImprovement of Left Ventricular Assist Device (LVAD) in Artificial Heart Using Particle Swarm Optimization
In this approach, the Left ventricular assist pump for patients with left ventricular failure isused. The failure of the left ventricle is the most common heart disease during these days. Inthis article, a State feedback controller method is used to optimize the efficiency of a samplingpump current. Particle Swarm Algorithm, which is a set of rules to update the position andvelocity, is applied...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2015